Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 5/20 | 0.66 |
| ▸ | MAG | P20916 | 6/20 | 0.62 |
| ▸ | SELP | P16109 | 2/20 | 0.62 |
| ▸ | SELL | P14151 | 1/20 | 0.62 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12903208 | 0.93 | SELE (0.62) | SELEMAGSELPSELLSIGLEC7 | |
| SCHEMBL22763983 | 0.91 | SELP (0.72) | SELEMAGSELPSELLSIGLEC7 | |
| SCHEMBL13541587 | 0.91 | SELP (0.72) | SELEMAGSELPSELLSIGLEC7 | |
| SCHEMBL12903211 | 0.91 | SELE (0.69) | SELEMAGSELPSELLSIGLEC7 | |
| SCHEMBL12903212 | 0.89 | SELE (0.67) | SELEMAGSELPSELLSIGLEC7 | |
| SCHEMBL12903210 | 0.88 | SELE (0.62) | SELEMAGSELPSELLSIGLEC7 | |
| SCHEMBL14268468 | 0.88 | SELP (0.70) | SELEMAGSELPSELLSIGLEC7 | |
| SCHEMBL14518953 | 0.88 | SELP (0.70) | SELEMAGSELPSELLSIGLEC7 | |
| SCHEMBL14331141 | 0.88 | SELP (0.70) | SELEMAGSELPSELLSIGLEC7 | |
| SCHEMBL17903030 | 0.87 | SELE (0.62) | SELEMAGSELPSELLSIGLEC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486497-B2 | Treatment of immunocompromised conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-11-08 | — | — | US | disclosed |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
| US-9254322-B2 | Compositions comprising E-selectin antagonists and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-02-09 | — | — | US | disclosed |
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE | 2011-01-27 | — | — | US | disclosed |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE (AU) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELL | SELE 2/4885MAG 1778/4885SELP 1/4885 |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELPLG | SELE 2/4885MAG 1675/4885SELP 1/4885 |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | SELL, SELP, SELE | SELE 3/4885MAG 979/4885SELP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.